Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.150 |
---|---|
High | 0.150 |
Low | 0.150 |
Bid | -- |
Offer | -- |
Previous close | 0.16 |
Average volume | -- |
---|---|
Shares outstanding | 165.93m |
Free float | 106.59m |
P/E (TTM) | -- |
Market cap | 13.31m GBP |
EPS (TTM) | -0.4325 GBP |
Data delayed at least 15 minutes, as of Oct 08 2024 15:29 BST.
More ▼
Announcements
- Commencement of trading on OTCQB in the United States
- Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US
- Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination
- Medicare Issues Final Coverage Determination for kidneyintelX.dkd
- Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024
- Renalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15
- Renalytix Announces Financing with Expected Size of up to $4 Million
- KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)
- Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024
- Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
More ▼